2579 related articles for article (PubMed ID: 28222828)
1. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
Jeanes YM; Reeves S
Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
[TBL] [Abstract][Full Text] [Related]
2. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
Graff SK; Mário FM; Alves BC; Spritzer PM
Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
[TBL] [Abstract][Full Text] [Related]
3. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
[TBL] [Abstract][Full Text] [Related]
5. Metabolic inflexibility in women with polycystic ovary syndrome: a systematic review.
Rimmer M; Tan BK; Teede H; Thangaratinam S; H Al Wattar B
Gynecol Endocrinol; 2020 Jun; 36(6):501-507. PubMed ID: 31793357
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and cardiovascular consequences of polycystic ovary syndrome.
Orio F; Vuolo L; Palomba S; Lombardi G; Colao A
Minerva Ginecol; 2008 Feb; 60(1):39-51. PubMed ID: 18277351
[TBL] [Abstract][Full Text] [Related]
7. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS.
Zheng SH; Li XL
Gynecol Endocrinol; 2016; 32(3):177-83. PubMed ID: 26502288
[TBL] [Abstract][Full Text] [Related]
8. A case-control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
Reprod Health; 2015 Jan; 12():7. PubMed ID: 25595199
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
[TBL] [Abstract][Full Text] [Related]
10. Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) as Markers of Insulin Resistance and Metabolic Associated Disturbances in Young Argentine Women with Polycystic Ovary Syndrome.
Abruzzese GA; Cerrrone GE; Gamez JM; Graffigna MN; Belli S; Lioy G; Mormandi E; Otero P; Levalle OA; Motta AB
Horm Metab Res; 2017 Jan; 49(1):23-29. PubMed ID: 27571188
[TBL] [Abstract][Full Text] [Related]
11. Metabolically healthy polycystic ovary syndrome (MH-PCOS) and metabolically unhealthy polycystic ovary syndrome (MU-PCOS): a comparative analysis of four simple methods useful for metabolic assessment.
Amato MC; Guarnotta V; Forti D; Donatelli M; Dolcimascolo S; Giordano C
Hum Reprod; 2013 Jul; 28(7):1919-28. PubMed ID: 23592224
[TBL] [Abstract][Full Text] [Related]
12. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Vassilatou E
World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
[TBL] [Abstract][Full Text] [Related]
14. Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.
Durmus U; Duran C; Ecirli S
J Endocrinol Invest; 2017 May; 40(5):487-497. PubMed ID: 27838846
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.
Petta S; Ciresi A; Bianco J; Geraci V; Boemi R; Galvano L; Magliozzo F; Merlino G; Craxì A; Giordano C
PLoS One; 2017; 12(11):e0186136. PubMed ID: 29161258
[TBL] [Abstract][Full Text] [Related]
16. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
Moghetti P; Tosi F; Bonin C; Di Sarra D; Fiers T; Kaufman JM; Giagulli VA; Signori C; Zambotti F; Dall'Alda M; Spiazzi G; Zanolin ME; Bonora E
J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
[TBL] [Abstract][Full Text] [Related]
17. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
Targher G; Rossini M; Lonardo A
Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975
[TBL] [Abstract][Full Text] [Related]
18. Comparison of metabolic and obesity biomarkers between adolescent and adult women with polycystic ovary syndrome.
de Medeiros SF; de Medeiros MAS; Barbosa BB; Yamamoto MMW; Maciel GAR
Arch Gynecol Obstet; 2021 Mar; 303(3):739-749. PubMed ID: 33201375
[TBL] [Abstract][Full Text] [Related]
19. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
Baranova A; Tran TP; Birerdinc A; Younossi ZM
Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
[TBL] [Abstract][Full Text] [Related]
20. A visceral adiposity index-related dietary pattern and the cardiometabolic profiles in women with polycystic ovary syndrome.
Ehsani B; Moslehi N; Mirmiran P; Ramezani Tehrani F; Tahmasebinejad Z; Azizi F
Clin Nutr; 2016 Oct; 35(5):1181-7. PubMed ID: 26699405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
